News | Antiplatelet and Anticoagulation Therapies | April 16, 2019

HonorHealth Research Institute Launches SynIVUS-DAPT Study

Study will investigate benefit of shortening dual antiplatelet therapy duration for patients at high bleeding risk after coronary stent implantation

HonorHealth Research Institute Launches SynIVUS-DAPT Study

April 16, 2019 — HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical study is designed to test outcomes of decreasing the amount of time patients with a high risk of bleeding take antiplatelet medications after receiving a drug-eluting coronary stent.

"People who receive drug-eluting stents are required to take antiplatelet medications for six to 12 months after stent placement," said David G. Rizik, M.D., chief scientific officer and director of structural and coronary interventions at HonorHealth Research Institute and principal investigator for the study. "These medications can exacerbate bleeding risk and therefore, being able to reduce the amount of time patients are on these dual antiplatelet regimens can be beneficial."

All five HonorHealth hospitals in the greater Phoenix area are participating in the study. Two other hospital systems also are participating:

  • Massachusetts General Hospital, under the direction of Farouc Jaffer, M.D., Ph.D., FACC, FAHA, FSCAI, director, coronary intervention and chronic total occlusion PCI program; associate physician, Massachusetts General Hospital (MGH) Cardiology, Department of Medicine; associate professor of medicine, Harvard Medical School; and
  • Northwell Hospital System in Long Island, N.Y., under the direction of Varinder P. Singh, M.D., FACC, FSCAI, chairman, Department of Cardiovascular Medicine Lenox Hill Hospital, Northwell Health; senior vice president, cardiology service line Northwell Health, Western Region.

Individuals in this study have developed a blockage in one or more arteries in their heart which may require a drug-coated stent to open the blockage(s). The study also uses an imaging procedure called intravascular ultrasound (IVUS) at the time of stent placement. The IVUS procedure looks at the placement of the stent to make sure it is fully opened and against the artery wall.

Individuals considered at high risk for bleeding include those who:

  • Are 75 and older;
  • Require blood-thinning medications for health issues such as blood clots or an irregular heart rhythm;
  • Have had a stroke; and
  • Are at risk for falling or other conditions that may put them at a high risk of bleeding.

For more information: www.honorhealth.com

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...